Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials

In previous phase I/II oncology trials for drug combinations, a number of methods have been studied to determine the dose combination for the next cohort. However, there is a risk that trial durations will be unfeasibly long if methods for evaluating safety and efficacy are based on the best overall...

Full description

Bibliographic Details
Main Authors: Shinjo Yada, Chikuma Hamada
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Contemporary Clinical Trials Communications
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865416301314

Similar Items